Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2020

Open Access 01-12-2020 | Nitrofurantoin | Case report

Reversible lung fibrosis in a 6-year-old girl after long term nitrofurantoin treatment

Authors: Lise Fischer Mikkelsen, Sune Rubak

Published in: BMC Pulmonary Medicine | Issue 1/2020

Login to get access

Abstract

Background

Pulmonary side effects are well known, including lung fibrosis, in elderly patients treated with long-term nitrofurantoin to prevent urinary tract infections and secondary renal injury. However, pulmonary side effects have only been reported rarely in paediatric cases, despite nitrofurantoin being a first line prophylactic treatment of recurrent childhood urinary tract infection.

Case presentations

A 6-year-old girl was admitted to the hospital with dyspnea, general fatigue, loss of appetite and need for nasal oxygen treatment after long-term nitrofurantoin treatment. A computed tomography scan of the chest showed lung fibrosis. A biopsy confirmed this diagnosis. We suspected the fibrosis to be caused by the nitrofurantoin treatment. Thorough examinations reveal no other explanations. Nitrofurantoin was discontinued and the girl was treated with methylprednisolone. After 17 month a new scan and lung function test showed total regression of the lung fibrosis.

Conclusions

This case underlines that risk of severe side effects should be taken in to account before initiation of long-term nitrofurantoin treatment in children.
Literature
1.
go back to reference Almeida P, Seixas E, Pinheiro B, Ferreira P, Araujo A. Consider nitrofurantoin as a cause of lung injury. Eur J Case Rep Intern Med. 2019;6(11):001295.PubMedPubMedCentral Almeida P, Seixas E, Pinheiro B, Ferreira P, Araujo A. Consider nitrofurantoin as a cause of lung injury. Eur J Case Rep Intern Med. 2019;6(11):001295.PubMedPubMedCentral
2.
go back to reference Kabbara WK, Kordahi MC. Nitrofurantoin-induced pulmonary toxicity: a case report and review of the literature. J Infect Public Health. 2015;8(4):309–13.CrossRef Kabbara WK, Kordahi MC. Nitrofurantoin-induced pulmonary toxicity: a case report and review of the literature. J Infect Public Health. 2015;8(4):309–13.CrossRef
3.
go back to reference Madani, et al. Nitrofurantoin-induced disease and prophylaxis of urinary tract infections. Prim Care Respir J. 2012;21(3):337–41.CrossRef Madani, et al. Nitrofurantoin-induced disease and prophylaxis of urinary tract infections. Prim Care Respir J. 2012;21(3):337–41.CrossRef
5.
go back to reference Karpman E, Kurzrock EA. Adverse reactions of nitrofurantoin, trimethoprim and sulfanethoxazole in children. J Urol. 2004;172(2):448–53.CrossRef Karpman E, Kurzrock EA. Adverse reactions of nitrofurantoin, trimethoprim and sulfanethoxazole in children. J Urol. 2004;172(2):448–53.CrossRef
6.
go back to reference Hage P, El Hajje MJ. Nitrofurantoin-induced desquamative interstitial pneumonitis in a 7-year-old child. Pediatr Infect Dis J. 2011;30(4):363.CrossRef Hage P, El Hajje MJ. Nitrofurantoin-induced desquamative interstitial pneumonitis in a 7-year-old child. Pediatr Infect Dis J. 2011;30(4):363.CrossRef
7.
go back to reference Williams G, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev. 2019;4:CD001534.PubMed Williams G, Craig JC. Long-term antibiotics for preventing recurrent urinary tract infection in children. Cochrane Database Syst Rev. 2019;4:CD001534.PubMed
8.
go back to reference Tullus K, Shaikh N. Urinary Tract Infections in Children. Lancet 2020 May 23;395(10237. Tullus K, Shaikh N. Urinary Tract Infections in Children. Lancet 2020 May 23;395(10237.
10.
go back to reference Subcommittee on Urinary Tract Infection Reaffirmation of AAP Clinical Practice Guideline. The diagnosis and management of the initial urinary tract infection in febrile infants and young children 2–24 months of age. Pediatrics. 2016;138(6):20163026.CrossRef Subcommittee on Urinary Tract Infection Reaffirmation of AAP Clinical Practice Guideline. The diagnosis and management of the initial urinary tract infection in febrile infants and young children 2–24 months of age. Pediatrics. 2016;138(6):20163026.CrossRef
11.
go back to reference Syed H, Bachuwa G, Upadahyaa S, Abed F. Nitrofurantoin-induced interstitial pneumonitis: albeit rare, should not be missed. BMJ Case Rep. 2016: bcr2015213967. Syed H, Bachuwa G, Upadahyaa S, Abed F. Nitrofurantoin-induced interstitial pneumonitis: albeit rare, should not be missed. BMJ Case Rep. 2016: bcr2015213967.
Metadata
Title
Reversible lung fibrosis in a 6-year-old girl after long term nitrofurantoin treatment
Authors
Lise Fischer Mikkelsen
Sune Rubak
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2020
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-020-01353-x

Other articles of this Issue 1/2020

BMC Pulmonary Medicine 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.